CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,032 | -16.9% | 2,292 | +2.8% | 0.00% | – |
| Q2 2023 | $125,193 | +48.3% | 2,230 | +19.4% | 0.00% | – |
| Q1 2023 | $84,444 | +52.3% | 1,867 | +36.9% | 0.00% | – |
| Q4 2022 | $55,446 | -62.0% | 1,364 | -39.0% | 0.00% | – |
| Q3 2022 | $146,000 | +160.7% | 2,237 | +142.9% | 0.00% | – |
| Q2 2022 | $56,000 | +80.6% | 921 | +86.8% | 0.00% | – |
| Q1 2022 | $31,000 | -47.5% | 493 | -36.6% | 0.00% | – |
| Q4 2021 | $59,000 | -32.2% | 778 | 0.0% | 0.00% | – |
| Q3 2021 | $87,000 | -37.4% | 778 | -9.1% | 0.00% | – |
| Q2 2021 | $139,000 | +247.5% | 856 | +163.4% | 0.00% | – |
| Q1 2021 | $40,000 | +400.0% | 325 | +550.0% | 0.00% | – |
| Q4 2020 | $8,000 | +60.0% | 50 | -13.8% | 0.00% | – |
| Q3 2020 | $5,000 | – | 58 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |